Skip to content

OncoMed Pharmaceuticals Inc

CIK 0001302573

← back to feed
Revenue (TTM)
$10.18M
−47.8% YoY FY Mar 2019
Net Income (TTM)
−$14.13M
−176.3% YoY FY Mar 2019
EPS Diluted (TTM)
−$0.21
FY Mar 2019
Gross Margin
—
FY Mar 2019
Operating Margin
-157.6%
FY Mar 2019
Net Margin
-138.7%
FY Mar 2019
Free Cash Flow (TTM)
−$46.35M
FY Mar 2019
Cash
$9.69M
FY Mar 2019
Total Debt
—
FY Mar 2019
Shares Outstanding
38.69M sh
FY Mar 2019

Revenue & Net Income

EPS (Diluted)

Margins

Cash Flow

Revenue Growth (YoY)

Balance Sheet

Cash vs Debt

Recent filings